TechSmith Debuts Camtasia Online, the Free Web-based Version of the Award-Winning Screen Recorder and Editor
EAST LANSING, Mich., June 17, 2025 (GLOBE NEWSWIRE) -- TechSmith Corporation, an industry leader in visual communication, released Camtasia online, a free lite web-based version of its industry-leading screen recorder and video editor, Camtasia, used by more than 34 million people globally. The streamlined experience of the popular screen recorder enables users to create, customize, share, and collaborate on high-quality videos for free with no software download, subscription, or watermark. The solution is ideal for creating step-by-step walkthroughs and tutorials, providing personalized feedback or coaching, and showcasing a product or service.
'We're excited to launch the first free, online version of Camtasia—a foundational step in bringing the power of our award-winning solution to more people, right in their browser,' said Tony Lambert, CTO of TechSmith. 'Video is a team sport now, and Camtasia online makes it easier for creators of all skill levels to collaborate and create high-quality content from anywhere. While this first release focuses on streamlined creation, it will continue to grow in capability, and users can move projects into the Camtasia desktop editor for more advanced editing when needed.'
Camtasia online features
High-quality screen recording: Capture crystal-clear five-minute scenes in 1080p HD with flexible options for application-specific or full-screen recording, ensuring every detail is sharp and professional. Camtasia online records screen, camera, and microphone on separate layers to offer maximum editing flexibility.
Endless design options: Choose from 85+ pre-defined 'looks' that match your style and then customize further with thousands of different effects and backgrounds for both camera and screen. Enjoy features like background removal, borders, drop shadows, corner rounding, masks, and reflections — all of which can be applied before or after recording.
Effortless editing: Quickly trim video scenes. Every edit is completely reversible, giving users the freedom to refine content stress-free.
Seamless collaboration: Invite others to collaborate on entire projects or assign access to specific scenes.
Flexible export and sharing options: Publish a Camtasia online project via link share or export directly to Camtasia 2025's desktop editor to take advantage of enhanced capabilities including transitions, annotations, and dynamic captions.
Camtasia online is available for free today on popular web browsers including Google Chrome and Safari. Start recording at https://camtasia.techsmith.com/.
About CamtasiaCamtasia is an industry-leading screen recording, video, and audio editing solution to simplify the creation of high-quality tutorials, demos, training, and visual content. With a rich, expansive, and flexible feature set, Camtasia has the lowest barrier of entry of any recording and editing software, helping users educate, inspire, and excite their audience with professional-quality videos. Its intuitive Camtasia Rev workflow guides users through various size, layout, background, effect, and filter choices, empowering users of all skill levels to quickly create professional quality videos. Camtasia is used by more than 34 million people globally, including all Fortune 500 companies like Apple, Microsoft, Amazon and Google. In 2024, Camtasia was rated a top 5 screen and video capture solution by G2's community of reviewers. Camtasia is offered both as a full-featured desktop application and a streamlined web-based version, which also integrates seamlessly with the main editor. For more information, visit www.techsmith.com/video-editor.html. Connect with Camtasia on LinkedIn, X, Facebook, and Instagram. For more information, visit https://www.techsmith.com/camtasia/.
About TechSmithTechSmith is the market leader in screen capture software and productivity solutions for daily in-person, remote or hybrid workplace communication and customer-facing image and video content. The company's award-winning flagship products, Snagit, Camtasia, and Audiate empower anyone to create remarkable videos and images that share knowledge for better training, tutorials, and everyday communication. TechSmith creates easy-to-use software and provides expert training resources and unmatched support — making TechSmith the global leader for easily creating effective images and videos. To date, billions of images and videos have been created with TechSmith's products by more than 73 million people across more than 190 countries. TechSmith is ranked as a top 10 company in G2's Spring 2024 report and winner of a 2024 Training Magazine Network Choice Award. Connect with TechSmith on LinkedIn, X (formerly Twitter), and Facebook. For more information, visit www.techsmith.com.
Media Contact:Ross BlumeFusion Public Relationstechsmith@fusionpr.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions. Cogent intends to use the net proceeds from the offering for continued development, regulatory and commercial preparation activities relating to bezuclastinib and other product candidates, activities to support the planned commercial launch of bezuclastinib as well as for working capital and general corporate purposes. J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is also acting as lead manager for the offering. The securities described above are being offered pursuant to an automatic shelf registration statement on Form S-3ASR (File No. 333-269707), which was filed with the Securities and Exchange Commission (SEC) on February 10, 2023 and automatically became effective upon filing. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering were filed with the SEC on July 8, 2025. A final prospectus supplement and the accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC. The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering can be made only by means of a prospectus supplement and accompanying base prospectus, copies of which may be obtained at the SEC's website at or by request to J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@ and postsalemanualrequests@ Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@ or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., New York, NY 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@ About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors, a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the completion of the public offering and the use of proceeds therefrom, are forward-looking statements. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' and similar words or expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results, the rate of enrollment in our clinical trials and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts or milestones disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to our capital position and the sufficiency of our capital to fund our operations in future periods; our use of the net proceeds of the underwritten public offering; risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the underwritten public offering; the impact of general economic, health, industrial or political conditions in the United States or internationally; and other risks and uncertainties identified in our filings with the SEC, including our Registration Statement on Form S-3ASR, which was filed with the SEC on February 10, 2023 and automatically became effective upon filing, as may be amended from time to time, together with the accompanying base prospectus contained therein and the documents incorporated by reference therein, including our most recent Annual Report on Form 10-K, our Quarterly Report on Form 10-Q and our subsequent periodic reports filed with the SEC, and the preliminary prospectus supplement related to this offering. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof. Contact: Christi WaarichSenior Director, Investor
Business Upturn
2 hours ago
- Business Upturn
ROHM Develops an Ultra-Compact MOSFET Featuring Industry-Leading* Low ON-Resistance Ideal for Fast Charging Applications
Santa Clara, CA and Kyoto, Japan, July 08, 2025 (GLOBE NEWSWIRE) — ROHM Semiconductor today announced the development of the AW2K21, a 30V N-channel MOSFET in a common-source configuration that delivers an industry-leading ON-resistance of just 2.0mΩ (typ.) in a compact 2.0mm × 2.0mm package. With the rise of compact devices featuring large-capacity batteries, such as smartphones, the need for fast charging functionality to shorten charging times continues to grow. These applications require bidirectional protection to prevent reverse current flow to peripheral ICs and other components when not actively supplying or receiving power. What's more, fast charging involves high current power transfer, leading smartphone manufacturers to demand stringent specifications for MOSFETs, including a maximum current rating of 20A, breakdown voltage between 28V and 30V, and an ON-resistance of 5mΩ or less. However, meeting these requirements with standard solutions typically necessitates the use of two large low ON-resistance MOSFETs, increasing board space along with mounting complexity. In response, ROHM developed an ultra-compact low ON-resistance MOSFET optimized for fast high-power charging. The AW2K21 adopts a proprietary structure that enhances cell density while minimizing the ON-resistance per unit chip area. Two MOSFETs are integrated into a single package, allowing a single part to support bidirectional protection applications (commonly required in power supply and charging circuits). The proprietary structure also places the drain terminal on the top surface, unlike on the backside in standard vertical trench MOS structures. This enables the use of a WLCSP, which achieves a larger chip-to-package area ratio that further reduces ON-resistance per unit area. As a result, the new product not only minimizes power loss but also supports high current operation, making it ideal for high-power fast charging applications despite its ultra-compact size. For example, in power supply and charging circuits for compact devices, standard solutions typically require two 3.3mm × 3.3mm MOSFETs. In contrast, the AW2K21 can achieve the same functionality with a single 2.0mm × 2.0mm unit, reducing the footprint and ON-resistance by approximately 81% and 33%, respectively. Even compared to similarly sized GaN HEMTs, ON-resistance is decreased by up to 50%, contributing to lower power consumption and increased space savings across a variety of applications. The AW2K21 is also suitable for use as a unidirectional protection MOSFET in load switch applications, where it maintains the industry's lowest ON-resistance. At the same time, ROHM is further pushing the limits of miniaturization with the development of an even smaller 1.2mm × 1.2mm model. Going forward, ROHM remains dedicated to supporting the miniaturization and energy efficiency of electronic systems through compact, high-performance solutions that contribute to the realization of a sustainable society. Online Sales Information Sales Launch Date: April 2025 Online Distributors: DigiKey™, Mouser™ and Farnell™ Applicable Part No: AW2K21 The product will be offered at other online distributors as it becomes available. Note: DigiKey™, Mouser™ and Farnell™ are trademarks or registered trademarks of their respective companies. _______________________________________________________________________________________________________________________________________ *ROHM July 2025 study Attachments ROHM Develops the AW2K21, a 30V N-Channel MOSFET Comparison Between Standard Products and ROHM's New Product the AW2K21 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Upturn
2 hours ago
- Business Upturn
Zig-Zag Launches New Premium Natural Leaf Cigar Line – Zig-Zag Woods
By GlobeNewswire Published on July 9, 2025, 02:53 IST Los Angeles, California, July 08, 2025 (GLOBE NEWSWIRE) — Zig-Zag Launches New Premium Natural Leaf Cigar Line – Zig-Zag Woods Slow-Burning, Boldly Flavored, and Value-Priced for High Turnover in Convenience and Smoke Shop Channels Zig-Zag, a heritage brand trusted by millions, proudly announces the launch of Zig-Zag Woods, a new line of premium natural leaf cigars crafted for today's adult cigar consumer and strategically designed for convenience stores and smoke shops. With more than 58% of consumers referring to rough-cut cigars as 'woods', this launch meets consumer expectations with a name and format that resonates. Zig-Zag Woods features a slow-burning, all-natural leaf wrap filled with premium rough-cut tobacco, delivering a rich and smooth smoking experience. With bold flavor profiles and recognizable Zig-Zag branding, this line is engineered for fast sell-through and high margins. Over 300 million rough-cut cigars are sold annually (MSA), demonstrating the strength of this segment, and Zig-Zag Woods is primed to compete and win. Product Offering: 5 Varieties: Natural Silk & Berries Sweet Aromatic Crème Royale Velvet Pre-Priced: $1.39 for 2 cigars $1.39 for 2 cigars Packaging Configuration: 15 pouches per carton 24 cartons per case Whether your customers prefer the boldness of Sweet Aromatic or the smoothness of Velvet, Zig-Zag Woods provides a flavor for every taste. With its competitive price point, premium quality, and shelf-ready format, Zig-Zag Woods is primed to become a top seller in the natural leaf cigar segment. 'Customers have been asking for a premium value-added product that moves quickly and satisfies customers. Zig-Zag Woods is our answer,' said Jessica Chesney, SBM of Marketing at Zig-Zag. 'We've combined quality, flavor variety, and value into a package that's a win for both consumers and the trade.' Now Shipping Nationwide Zig-Zag Woods are now available for wholesale and retail ordering. For more information, promotional assets, or to place an order, contact Zig-Zag customer service at (800) 331-5962 [email protected] or visit TPB Marketplace. About Zig-Zag Zig-Zag is a market leader in premium tobacco and smoking accessories, known for its authenticity, innovation, and quality. With a legacy spanning over 140 years, Zig-Zag continues to evolve with consumer trends while delivering reliable products to its retail partners. Zig-Zag is exclusively distributed by Turning Point Brands (NYSE: TPB), a manufacturer, marketer, and distributor of branded consumer products. Attachment Zig-Zag Launches New Premium Natural Leaf Cigar Line – Zig-Zag Woods Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
